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Purpose: To investigate the influence of induction chemotherapy (ICT) on dosimetric outcomes in patients with
inoperable non-small cell lung cancer (NSCLC) treated with definitive chemoradiation (CRT).
Materials and methods: 30 patients with inoperable stage II-III NSCLC treated with 2–4 cycles of ICT followed by
definitive CRT to ≥ 60 Gy were selected. Tumor response to chemotherapy was scored by RECIST criteria. Treatment
plans based on tumor extent prior to chemotherapy were generated based on equivalent planning constraints and
techniques as the original post-chemotherapy plans. Dosimetric parameters predictive of toxicity for lung, esophagus,
heart, and spinal cord were compared amongst the pre- and post-ICT plans.
Results: The majority of patients (70%) experienced an overall reduction in GTV size between the pre-ICT imaging and
the time of simulation. Comparing pre-and post-ICT diagnostic imaging, 5 patients met the RECIST criteria for response,
23 were classified as stable, and 2 experienced disease progression on diagnostic imaging. Despite a significantly
reduced GTV size in the post-ICT group, no systematic improvements in normal tissue doses were seen amongst the
entire cohort. This result persisted amongst the subgroup of patients with larger pre-ICT GTV tumor volumes (>100 cc3).
Among patients with RECIST-defined response, a significant reduction in lung mean dose (1.9 Gy absolute, median 18.2
Gy to 16.4 Gy, p = 0.04) and V20, the percentage of lung receiving 20 Gy (3.1% absolute, median 29.3% to 26.3%, p = 0.04)
was observed. In the non-responding group of patients, an increased esophageal V50 was found post-chemotherapy
(median 28.9% vs 30.1%, p = 0.02).
Conclusions: For patients classified as having a response by RECIST to ICT, modest improvements in V20 and mean
lung dose were found. However, these benefits were not realized for the cohort as a whole or for patients with larger
tumors upfront. Given the variability of tumor response to ICT, the a priori impact of induction chemotherapy to
reduce RT dose to normal tissue in these patients is minimal in the setting of modern treatment planning.Introduction
In the treatment of non-small cell lung cancer (NSCLC),
induction chemotherapy (ICT) is commonly used as a
means of cytoreduction to reduce subsequent radiother-
apy field size or to convert a previously unresectable
lung tumor to resectability. The actual impact, however,* Correspondence: jdgrant@mdanderson.org; dgomez@mdanderson.org
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normal tissues using modern techniques in clinical prac-
tice is not well studied. ICT has not been shown to confer
survival advantage in a sequential approach with concur-
rent chemoradiotherapy (CRT) and confers added toxicity
and treatment time [1,2].
Given these costs, we sought to investigate dosimetric
impact of ICT in 30 sequential patients treated with a
homogeneous and well-accepted regimen of ICT followedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline patient and treatment characteristics
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effects of ICT on target and normal tissue dosimetric
variables were quantified in this population by com-
paring treatment plans generated from pre- and post-
chemotherapy volumes, both as an entire cohort and













N0 2Methods and materials
Patient characteristics
Appropriate MD Anderson Institutional Review Board
approvals were obtained. We retrospectively reviewed our
institutional records from 2007 to 2010 and selected 30
consecutive patients that met the following criteria: (a)
Stage II-III NSCLC (according to the 7th edition of the
American Joint Committee on Cancer staging manual
[3]), (b) treated with an ICT regimen 2–4 cycles of a plat-
inum/taxol doublet, (c) for whom a diagnostic CT scan
prior to initiation of chemotherapy was available for re-
view, (d) who were then treated with definitive CRT to a
radiation dose ≥ 60 Gy. A summary of patient and disease

















Abbreviations: ICT induction chemotherapy, RT radiotherapy.Chemotherapy
Patients received ICT for a variety of reasons, including:
1) cytoreduction in an attempt to render the patient’s
disease operable or reduce radiation toxicity (18 patients)
and 2) questionable metastatic disease on imaging, such
that chemotherapy was given to allow patients to “declare”
themselves as having true locoregional versus metastatic
malignancy prior to a definitive course of radiation ther-
apy (5 patients). The reason for induction chemotherapy
administration was not explicitly stated in 7 patients. All
patients received 2–4 cycles of a platinum/taxol doublet.
15 patients received carboplatin-based therapy, and 15
received cisplatin-based therapy. 23 patients were treated
with taxotere, and 7 with paclitaxel. 15 patients received
2 cycles of ICT, 11 were treated with 3 cycles, and 4 re-
ceived 4 cycles. The median time interval from the final
day of chemotherapy administration to RT start was
1.1 months (range 0.1-3.5 months).
The pre- and post-ICT diagnostic CT scans were
reviewed and scored by a single investigator (JG) accord-
ing to the Response Evaluation Criteria for Solid Tumors
(RECIST) guidelines [4]. Tumor size was obtained by
direct measurements on the CT scans. In accordance
with the RECIST grading system, complete response was
defined as disappearance of all target lesions; a partial
response was represented by a 30% or greater decrease
in the sum of the longest diameter of target lesions;
and progressive disease was an increase of 20% or
more in these parameters, or any new sites of disease.
Changes not meeting any of these criteria were defined as
stable disease. For the purposes of analysis, patients withstable and progressive disease were grouped as non-
responders.
Radiotherapy
Definitive CRT was delivered with intensity modu-
lated radiation therapy (IMRT) in 28 patients, and 3-D
conformal therapy in 2 patients. Simulation was per-
formed with 4DCT, and the gross tumor volume including
the primary lung tumor and involved lymph nodes was
contoured across all phases of the respiratory cycle to
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for the delivered post-ICT plans was completed by a var-
iety of attending physicians at our institution. Though in-
dividual approaches were varied, standard institutional
contouring techniques include nodal levels involved pre-
chemotherapy and post-chemotherapy parenchymal vol-
umes. Lung windows were used to define the extent of
parenchymal disease, with soft tissue windows to identify
mediastinal and lymph node disease. A 6- to 8-mm expan-
sion was applied from the iGTV structure to create the
clinical target volume (iCTV, approximating the ITV),
which was modified based on surrounding anatomic
structures. A 5-mm expansion was added to the CTV to
create a planning treatment volume (PTV).
A range of radiation doses were used, based on the
preference of the treating physician and the enroll-
ment of patients on dose-escalation protocols. 1 pa-
tient was treated to a radiation dose of 60 Gy, 5
received 63 Gy, 6 received 66 Gy, 6 received 70 Gy,
and 12 received 74 Gy. Dose per fraction ranged from
1.8 to 2.4 Gy.
Delineation of pre-ICT tumor volumes
In delimitating the pre-ICT tumor volumes, the diagnos-
tic CT obtained immediately prior to ICT administration
were spatially overlaid onto the post-ICT simulation CT
dataset. Using anatomic landmarks including bones and
cardiopulmonary structures to visually guide contour
delination, two investigators (JG and DG) recreated the
pre-ICT tumor volume on the post-ICT image set. iCTV
and PTV expansions were applied to match the tech-
nique used in the post-ICT planning process. Because
target volumes were transferred onto the post-ICT data-
set, identical normal tissue ROI contours could be pre-
served despite the difference in setup positioning between
the diagnostic and simulation CT scan. Normal lung vol-
umes, which are defined at our institution by subtracting
the GTV from the total lung volume, were recalculated
for the pre-ICT setting given the difference in GTV size
between the datasets.
Two medical dosimetrists (AS and EH) then generated
radiation plans based on these pre-ICT target volumes,
to the same prescription dose and using the same target
goals and normal tissue constraints (see Figure 1). For
treatment planning, class solutions were applied with
templated beam arrangements and planning objectives
based on the tumor location and extent. Standard in-
stitutional normal tissue dose constraints for concur-
rent CRT are found in Table 2. Dose was minimized
to the surrounding normal tissue ROIs while keeping
95% of the PTV covered by 95% of the prescription
dose (PTV95 ≥ 95%). In circumstances where a large tumor
size precluded the ability to achieving these constraints,
target coverage was sacrificed in order to maintain normaltissue constraints, allowing PTV95 to serve as single vari-
able for comparison in these cases.
In patients where updated institutional planning tech-
niques resulted in significant differences in beam arrange-
ment and overall plan quality, post-chemotherapy plans
were also re-planned using current methods consisting of
template beam arrangements based on the position of the
tumor within the thorax. Dose-volume histogram (DVH)
data points for targets and normal structures for both pre-
ICT and post-ICT plans were extracted using relational
database software [5]. The following parameters were
collected: lung V5 and V20, mean lung dose, maximum
spinal cord dose, heart mean, heart V40, esophagus mean,
esophagus V50, and maximum esophageal dose.
Statistical methods
A Wilcoxon matched-pairs signed-ranks test method
was used to determine significant differences between
the pre- and post-chemotherapy plans with regards to
the GTV, CTV and PTV sizes, dose to 95% of the GTV
(GTV95), CTV95, PTV95, and the normal regions of inter-
est as described above. These values were compared across
the entire cohort as well as segregated by RECIST classi-
fication and pre-chemotherapy GTV size > or ≤ 100 cc3.
P values ≤0.05 were considered to indicate statistically
significant differences. Stata/MP version 13.1 (College
Station, TX) was used for all statistical tests.
Results
Median time from completion of the last chemotherapy
course to radiation simulation was 18 days. Comparing
pre- and post-ICT diagnostic CT scans by RECIST cri-
teria, 5 (17%) had a partial response, 23 (77%) had stable
disease, and 2 (7%) had progressive disease. By absolute
GTV volume change between the pre-ICT diagnostic
scan and the RT simulation scan, 23 (77%) had unchanged
or smaller volumes after chemotherapy (Figure 2), while
in 7 (23%) the volume had increased. All normal tissue
dose constraints were met in each patient. In 5 patients, a
PTV95 of ≥95% was not achievable in pre-ICT plans and
coverage was thus sacrificed.
As shown in Figure 3, two patients experienced sig-
nificantly improved PTV coverage following ICT (ap-
proximately 7.5% absolute improvement), one of whom
achieved a PTV95 ≥ 95%. 2 patients with adequate PTV95
coverage on the pre-ICT plan showed significantly de-
creased target volume coverage on the post-ICT plans. A
total of 4 patients with compromised PTV95 had a >5%
difference between pre-ICT and post-ICT plans, 2 of
whom had improved coverage following ICT, and in 2 of
whom coverage decreased (Figure 4).
Results of the collective DVH analysis of target vol-
umes, target coverage, and dose to normal tissues are
represented in Table 3. No target coverage parameters
Figure 1 Gross tumor volumes (GTVs) on CT scans obtained before and after induction chemotherapy in a representative case. The
pretreatment GTV was first contoured on a diagnostic CT scan obtained before chemotherapy (A) and overlaid on the simulation CT (B), and a radiation
therapy plan was generated based on normal tissue contours on the simulation scan. After chemotherapy, the GTV was outlined on the simulation CT by
the treating physician (C) and the subsequent radiation treatment was planned according to institutional standards as described in the text (D).
Table 2 Institutional planning constraints for concurrent






























































Figure 2 Differences in contoured GTV size following ICT,
displayed as a percentage of pre-ICT volume. Positive values
indicate a GTV that has reduced in size following ICT, and negative







































Figure 3 PTV95 coverage (displayed as a percentage of prescribed dose) for pre-ICT versus post-ICT plans. 5 patients had initial pre-ICT
plans that did not meet target coverage goals, of whom 2 derived benefit from chemotherapy (patients 1 and 6). 2 plans (patients 2 and 7)
showed >5% compromised coverage for tumor volumes present following ICT.
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as compared to after ICT. Among the 5 who experienced
a RECIST response, a significantly decreased mean lung
dose (median 18.2 Gy vs 16.4 Gy, p = 0.04) and lung V20
(median 29.3% vs 26.3%, p = 0.04) was seen in the
post-chemotherapy plans. In the non-responding group
of patients, an increased esophageal V50 was found post-
chemotherapy (median 28.9% vs 30.1%, p = 0.02). No dif-
ferences in normal tissue doses were observed when









































Figure 4 Four patients showed a >5% difference between
pre- and post-ICT PTV95 coverage. One patient met target
coverage goals following ICT, two patients lost acceptable coverage
following ICT, and one patient derived benefit but remained below
the goal of 95%.Discussion
We present herein an investigation into the practical
impact of ICT on subsequent radiation planning using
modern techniques using IMRT with optimized class-
solutions based dosimetry. Target volumes using pre-
ICT extent of disease were recreated on the simulation
CT scan and compared with the actual post-ICT radi-
ation plans to determine differences. This was performed
on 30 consecutive patients for whom complete data and
imaging was available. A significant reduction in GTV
and CTV volumes was observed across the cohort fol-
lowing ICT; reduction in PTV volumes trended towards
but did not reach significance. As an entire cohort these
changes did not translate into clinically-relevant differ-
ences in normal tissue doses. Amongst patients with a
response by RECIST criteria, reductions were seen in
lung dose, with increased esophageal dose in RECIST-
defined stable and progressive patients. Amongst patients
with a larger initial tumor size (<100 cc3), greater tumor
shrinkage was likewise observed, but this did not translate
into any systematically reduced dose to normal tissues.
This is the first study to our knowledge which investi-
gates the impact of ICT on dosimetric outcomes using
modern planning techniques including IMRT. A previous
report by Jenkins et al. evaluated the impact of chemo-
therapy on subsequent 3D conformal hyperfractionated
RT [6]. 38 patients with unresectable stage III NSCLC
were treated with an induction chemotherapy regimen
consisting of mitomycin C, vinblastine, and carboplatin. A
three-field RT technique was used to deliver continuous
hyperfractionated accelerated RT to a dose of 56 Gy in 36
fractions given three times a day. 95% of patients
Table 3 Median values for dosimetric variables derived from scans obtained before and after induction chemotherapy
All patients (n = 30) RECIST responders
(n = 5)
RECIST stable and
progressive (n = 25)
Pre-ICT GTV >100 cc3
(n = 21)
Pre-ICT GTV ≤100 cc3
(n = 9)
Variable Pre-ICT Post-ICT P* Pre-ICT Post-ICT P* Pre-ICT Post-ICT P* Pre-ICT Post-ICT P* Pre-ICT Post-ICT P*
GTV size, cm3 117 111 0.02 117 62 0.04 115 115 0.14 134 126 0.04 57 40 0.26
CTV size, cm3 344 297 0.03 350 218 0.04 338 338 0.22 372 379 0.03 193 160 0.86
PTV size, cm3 546 559 0.37 617 376 0.04 528 574 0.76 606 621 0.22 312 342 0.51
GTV95, % 100 100 0.73 100 100 0.32 100 100 0.99 100 100 0.74 100 100 0.32
CTV95, % 100 100 0.15 100 100 0.40 100 100 0.23 100 100 0.36 100 100 0.40
PTV95, % 96.7 96.1 0.31 98.6 99.1 0.89 96.5 94.8 0.26 96.5 95.0 0.43 97.0 97.3 0.37
Lung V5, % 50.5 51.8 0.31 50.0 51.2 0.14 50.5 52.6 0.68 52.5 52.2 0.20 50.0 51.2 0.95
Lung V20, % 29.1 28.9 0.24 29.3 26.3 0.04 28.9 29.6 0.86 29.5 29,6 0.61 27.9 27.9 0.11
Lung mean
dose, Gy
18.1 18.5 0.45 18.2 16.4 0.04 18.1 18.6 0.68 18.2 18.5 0.96 16.1 18.6 0.11
Esophagus
mean dose, Gy
28.2 28.4 0.24 26.7 24.0 0.89 28.7 28.4 0.20 31.4 32.3 0.42 22.2 22.2 0.44
Esophagus
max, Gy
74.3 76.5 0.56 68.9 67.3 0.22 75.2 76.6 0.27 75.2 76.4 0.97 73.3 76.6 0.21
Esophagus
V50, %
29.0 28.9 0.08 32.4 20.9 0.22 28.9 30.1 0.02 32.1 31.7 0.10 23.8 23.5 0.34
Heart mean
dose, Gy
11.1 11.3 0.29 6.3 6.0 0.22 12.6 13.3 0.49 12.6 15.4 0.43 6.6 10.2 0.44
Heart V40, % 8.6 7.0 0.63 4.6 3.5 0.17 9.4 8.84 0.86 11.2 10.8 0.70 3.5 6.8 0.50
Spinal cord
max, Gy
42.3 42.7 0.19 42.7 41.7 0.5 42.3 42.8 0.25 42.8 43.1 0.33 39.2 41.7 0.37
Abbreviations: GTV gross tumor volume, CTV clinical target volume, PTV planning target volume.
*P values calculated with Wilcoxon matched-pairs signed-ranks test. Bolded p values are <0.05 and are taken as statistically significant.
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apy, compared to 70% in our study. Mean reductions after
chemotherapy was 37% for GTV and 26% for PTV. The
only dosimetric measure which was statistically improved
was lung V20, with a mean decrease in 3%. No differences
were seen in maximum esophageal or spinal cord dose fol-
lowing chemotherapy.
In contrast, we found no improvement across any
dosimetric parameter when evaluating the entire cohort.
Among RECIST responders, our findings paralleled those
reported by Jenkins et al., with a 3% reduction in V20. We
also report a median 2 Gy reduction in mean lung dose
for responders. Jenkins et al. quantified the location of
tumor shrinkage, finding the greatest effect along tumor
edges opposite the mediastinum, and supporting the neg-
ligible sparing of centrally-situated structures near the
mediastinum. Our results support this finding, both as
an entire cohort and when evaluating only those with a
RECIST response; central structures including the
esophagus, spinal cord, and heart did not benefit from
any dose reduction following chemotherapy. The reduc-
tion in lung-specific parameters among RECIST re-
sponders supports the patterns of shrinkage along lung
parenchymal edges.In conjunction with prior studies in both NSCLC [6]
and SCLC [7], we found the reductions in PTV size to
be smaller in magnitude than the corresponding GTV
shrinkage. This may be due, in part, to the abutment of
tumor against anatomic boundaries from which CTV
coverage expansion is reduced. As tumor reduction occurs
away from these structures, the CTV expansion that is
allowed would effectively enlarge, negating the sparing
effects of this shrinkage. This is especially true for medias-
tinal nodal locations, where vessels, esophagus, and bron-
chus are typically excluded from CTV expansions.
Differences between the present study and that repor-
ted by Jenkins et al. include patient selection and plan-
ning technique, the former of which highlights some of
the limitations of this study. Because tumor size, loca-
tion, and response to ICT are all unique to individual
cases, generalized results are highly dependent on pa-
tient selection. Differences in the overall response rate of
our cohort compared with that reported by Jenkins et al.
may thus be due to differences in patient selection and
tumor characteristics. In an attempt to minimize bias,
we selected the 30 most recent patients for whom all
needed datasets were available. The clinical indications
for ICT were varied (see Methods and materials), and
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were generated on the disease extend prior to chemo-
therapy. Even among those with compromised pre-ICT
coverage, however, showed limited benefit (Figure 3).
Differences are also likely influenced by our application of
modern techniques for RT planning, included IMRT and
class-solution algorithms for optimized planning. Com-
pared with the standard 3-field technique employed
by Jenkins et al., the plans generated in the present
study are likely to lessen the detriment of larger tumor
size on surrounding normal structures by improved dosi-
metric techniques.
Additional limitations of the present study include vari-
ation in chemotherapy agents used, timing of treatment,
and physician definition of post-ICT target volumes. These
factors also render the present study a real-world reflection
of clinical practice. The slight variations in physician tech-
nique (i.e. 6 versus 8 mm iCTV expansion) were repro-
duced in the pre-ICT planning process. Though simulation
CT scans were 4D and diagnostic CT scans were typically
in the breath-hold position, anatomic landmarks were used
to accurately depict pre-ICT tumor volume on the simula-
tion CT. Limitations in reconstructing pre-chemotherapy
volumes and tumor measurement are previously-described
[8,9]. PET-CT based measures of response could not be
evaluated as not all patients had this study performed.
As a result of these limited dosimetric improvements and
the difficulty in distinguishing peri-tumoral inflammation
from microscopic tumor following chemotherapy, Jenkins
et al. recommend targeting the tumor volumes present
prior to ICT in most patients. Given these reported uncer-
tainties, the known lack of survival benefit with the addition
of ICT to CRT, and the lack of dosimetric benefit we found
amongst the entire cohort, these findings discourage against
the general upfront use of ICT for patients with NSCLC. If
a significant response by RECIST could be expected, a
modest reduction in V20 and mean lung dose on the order
of 3% and 2 Gy, respectively, could be anticipated. Based
on the nomogram reported by Bradley et al., however,
these values are not likely to decrease the risk of
radiation pneumonitis by more than 5% [10]. Further
research to identify patients whose tumors are more
biologically likely to respond to ICT would allow this
practice to be applied selectively to those who would
derive the most benefit.
Conclusions
In this dosimetric planning study, we found no signifi-
cant decreases in normal tissue radiation doses following
ICT for the cohort as a whole. Although a modest
decrease in lung dose was observed in the subset of
responding patients by RECIST criteria, treatment re-
sponse to chemotherapy and the subsequent benefit
thereof cannot currently be predicted a priori. Given thelack of correlation of ICT response with a substantial clin-
ical or dosimetric benefit in our analysis, we recommend
that the decision to institute this treatment in an individ-
ual patient prior to definitive chemoradiation also be
weighed against the lack of an apparent survival advantage
in randomized studies and its associated toxicity.
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